{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T22:21:27Z","timestamp":1767046887911,"version":"3.37.3"},"reference-count":34,"publisher":"American Society of Hematology","issue":"19","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>von Willebrand disease (VWD) is an inherited bleeding disorder caused by quantitative or qualitative defects in the von Willebrand factor (VWF) protein. Type 3 VWD has a severe bleeding phenotype caused by the absence of VWF, in which treatment usually involves replacement therapy with VWF-containing products. The immune system can react to the VWF product and form anti-VWF antibodies to neutralize or clear the VWF, which can compromise efficacy of treatment or lead to anaphylaxis. Current diagnostic testing is limited to the detection of anti-VWF antibodies that neutralize VWF binding to platelets by using a ristocetin cofactor assay. We set out to develop assays to identify both neutralizing and nonneutralizing antibodies to screen, quantify, and characterize anti-VWF antibodies in samples from the Zimmerman Program, a large multicenter study of patients with VWD. We detected anti-VWF immunoglobulin G (IgG) or IgM antibodies in 18% of 49 unrelated individuals with type 3 VWD. The antibodies ranged in concentration and consisted of 33% nonneutralizing and 67% neutralizing to factor VIII, collagen III, platelet glycoprotein Ib alpha (GPIb\u03b1), and\/or collagen IV binding. Of the positive type 3 VWD samples, 8 of 9 were IgG, which were further subclassified into mostly IgG1 and IgG4 antibodies. Through a series of testing methods, we identified VWF-specific antibodies in 9 unrelated individuals with type 3 VWD with varying demographics, bleeding phenotypes, and genetic variants. This anti-VWF antibody testing strategy provides a useful tool to assess risk and better navigate treatment options for patients with type 3 VWD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013095","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T19:52:07Z","timestamp":1722541927000},"page":"5051-5061","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence and characterization of anti-VWF antibodies in a population of patients with type 3 VWD"],"prefix":"10.1182","volume":"8","author":[{"given":"Crystal L.","family":"Perry","sequence":"first","affiliation":[{"name":"1Versiti Blood Research Institute, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6758-9815","authenticated-orcid":false,"given":"Pamela A.","family":"Christopherson","sequence":"additional","affiliation":[{"name":"1Versiti Blood Research Institute, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina A.","family":"Agostini","sequence":"additional","affiliation":[{"name":"2Versiti Diagnostic Laboratories, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra L.","family":"Haberichter","sequence":"additional","affiliation":[{"name":"1Versiti Blood Research Institute, Milwaukee, WI"},{"name":"2Versiti Diagnostic Laboratories, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"Montgomery","sequence":"additional","affiliation":[{"name":"1Versiti Blood Research Institute, Milwaukee, WI"},{"name":"3Division of Hematology\/Oncology\/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI"},{"name":"4Children\u2019s Research Institute, Children\u2019s Hospital of Wisconsin, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-6838","authenticated-orcid":false,"given":"Veronica H.","family":"Flood","sequence":"additional","affiliation":[{"name":"1Versiti Blood Research Institute, Milwaukee, WI"},{"name":"3Division of Hematology\/Oncology\/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI"},{"name":"4Children\u2019s Research Institute, Children\u2019s Hospital of Wisconsin, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"issue":"10","key":"2024100813002028100_bib1","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2024100813002028100_bib2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","article-title":"ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease","volume":"5","author":"James","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2024100813002028100_bib3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) expert panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"issue":"7","key":"2024100813002028100_bib4","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/jth.15713","article-title":"Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman Program","volume":"20","author":"Christopherson","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9","key":"2024100813002028100_bib5","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"Rodeghiero","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2024100813002028100_bib6","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"5","key":"2024100813002028100_bib7","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jpba.2011.04.006","article-title":"A\u00a0formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays","volume":"55","author":"Jaki","year":"2011","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"6","key":"2024100813002028100_bib8","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1182\/blood-2010-08-299016","article-title":"Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the molecular and clinical biology of VWD","volume":"117","author":"Flood","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2024100813002028100_bib9","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/j.1538-7836.2010.03869.x","article-title":"Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD","volume":"8","author":"Flood","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"14","key":"2024100813002028100_bib10","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2014-11-610824","article-title":"Crucial role for the VWF A1 domain in binding to type IV collagen","volume":"125","author":"Flood","year":"2015","journal-title":"Blood"},{"issue":"20","key":"2024100813002028100_bib11","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2015-11-664680","article-title":"Rapid discrimination of the phenotypic variants of von Willebrand disease","volume":"127","author":"Roberts","year":"2016","journal-title":"Blood"},{"key":"2024100813002028100_bib12","unstructured":"U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Center for Biologics Evaluation and Research\n          . Immunogenicity testing of therapeutic protein products- developing and validating assays for anti-drug antibody detection: guidance for industry. 2019. Accessed 28 February 2024. https:\/\/www.fda.gov\/media\/119788\/download."},{"issue":"3","key":"2024100813002028100_bib13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood.V64.3.614.614","article-title":"Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies","volume":"64","author":"Mannucci","year":"1984","journal-title":"Blood"},{"issue":"10","key":"2024100813002028100_bib14","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood.V84.10.3378.3378","article-title":"Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen","volume":"84","author":"van Genderen","year":"1994","journal-title":"Blood"},{"key":"2024100813002028100_bib15","unstructured":"European Medicines Agency\n          . Guideline on immunogenicity assessment of therapeutic proteins (EMEA\/CHMP\/BMWP\/14327\/2006 Rev 1). 2017. Accessed 28 February 2024. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf."},{"key":"2024100813002028100_bib16","first-page":"109","article-title":"Antibodies to factor VIII-von Willebrand factor in congenital and acquired von Willebrand's disease","volume":"150","author":"Mannucci","year":"1984","journal-title":"Prog Clin Biol Res"},{"key":"2024100813002028100_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-4613-0331-2_7","article-title":"Antibodies to von Willebrand factor in von Willebrand disease","volume":"386","author":"Mannucci","year":"1995","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"2024100813002028100_bib18","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2516.2008.01679.x","article-title":"Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis [published correction appears in Haemophilia. 2009;15(2):637]","volume":"14","author":"Iorio","year":"2008","journal-title":"Haemophilia"},{"issue":"4","key":"2024100813002028100_bib19","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/hae.14266","article-title":"Inhibitor development in patients with type 3 Von Willebrand disease, a comprehensive study on 99 Iranian patients","volume":"27","author":"Jazebi","year":"2021","journal-title":"Haemophilia"},{"issue":"4","key":"2024100813002028100_bib20","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jtha.2023.01.001","article-title":"von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS","volume":"21","author":"Pagliari","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2024100813002028100_bib21","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2012-10-462085","article-title":"Alloantibodies in von Willebrand disease","volume":"122","author":"James","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2024100813002028100_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.V57.1.25.25","article-title":"Precipitating antibodies to factor VIII\/von Willebrand factor in von Willebrand's disease: effects on replacement therapy","volume":"57","author":"Mannucci","year":"1981","journal-title":"Blood"},{"key":"2024100813002028100_bib23","doi-asserted-by":"crossref","first-page":"807664","DOI":"10.3389\/fmed.2021.807664","article-title":"Rare occurrence of inhibitors in von Willebrand disease: a case report","volume":"8","author":"Kulkarni","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2024100813002028100_bib24","unstructured":"Diagnostic Laboratories Test Menu. Versiti. Accessed 28 February 2024. https:\/\/versiti.org\/diagnostic-labs-test-menu\/catalog\/anti-vwf-antibody-igg-and-igm."},{"issue":"4","key":"2024100813002028100_bib25","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1055\/s-0038-1656047","article-title":"Autoantibody selectively inhibits binding of von Willebrand factor to glycoprotein ib. Recognition site is located in the A1 loop of von Willebrand factor","volume":"77","author":"Mohri","year":"1997","journal-title":"Thromb Haemost"},{"issue":"7","key":"2024100813002028100_bib26","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"2024100813002028100_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1208\/s12248-012-9408-8","article-title":"Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics","volume":"15","author":"Zhou","year":"2013","journal-title":"AAPS J"},{"issue":"2","key":"2024100813002028100_bib28","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1055\/s-0037-1613799","article-title":"Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease","volume":"83","author":"Tout","year":"2000","journal-title":"Thromb Haemost"},{"key":"2024100813002028100_bib29","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"issue":"6","key":"2024100813002028100_bib30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0049-3848(01)00385-1","article-title":"Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease","volume":"104","author":"Matsumoto","year":"2001","journal-title":"Thromb Res"},{"issue":"1","key":"2024100813002028100_bib31","first-page":"60","article-title":"Familial incidence of precipitating antibodies in von Willebrand's disease: a study of four cases","volume":"94","author":"Ruggeri","year":"1979","journal-title":"J\u00a0Lab Clin Med"},{"issue":"1","key":"2024100813002028100_bib32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/blood.V72.1.116.116","article-title":"Further specificity characterization of von Willebrand factor inhibitors developed in two patients with severe von Willebrand disease","volume":"72","author":"L\u00f3pez-Fern\u00e1ndez","year":"1988","journal-title":"Blood"},{"issue":"7","key":"2024100813002028100_bib33","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood-2014-09-598268","article-title":"Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans","volume":"125","author":"Hofbauer","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2024100813002028100_bib34","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2014-05-378638","article-title":"von Willebrand factor, Jedi knight of the bloodstream","volume":"124","author":"Springer","year":"2014","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/19\/5051\/2245503\/blooda_adv-2024-013095-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/19\/5051\/2245503\/blooda_adv-2024-013095-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T16:28:37Z","timestamp":1728404917000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/19\/5051\/517260\/Prevalence-and-characterization-of-anti-VWF"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":34,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,10,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013095","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2024,9,26]]}}}